Eisai Co (ESALF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eisai Co. (ESALF) has reported an update for its Phase 2 trial of E7090 in advanced cholangiocarcinoma with FGFR2 gene fusion. The study, titled “A Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion,” aims to measure how many patients show tumor shrinkage after prior chemotherapy.
The treatment under review is E7090, an oral cancer drug taken once daily in 28 day cycles. It is designed to block FGFR2 related pathways that drive tumor growth in a subset of bile duct cancer patients who have limited options after standard chemotherapy has failed.
This is an interventional Phase 2 study with a single treatment arm, so all participants receive E7090 rather than being split into drug and control groups. The trial is open label, meaning both doctors and patients know they are receiving the drug, and the main goal is to evaluate treatment benefit rather than compare against a placebo.
The study was first submitted in January 2020, signaling the start of patient enrollment and early investor interest in this asset. The trial is now listed as completed, and the latest update on February 27, 2026 suggests that final data review and potential disclosure are close, a key point for traders watching the oncology pipeline.
For Eisai, positive response data in this niche but high need cancer could support a targeted launch, add to its oncology portfolio, and improve sentiment on ESALF as a precision oncology player. Investors should also watch peers with FGFR inhibitors in cholangiocarcinoma, as competitive data and pricing will shape revenue potential and valuation multiples.
The study of E7090 in unresectable advanced or metastatic cholangiocarcinoma is now completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about ESALF’s potential, visit the Eisai Co drug pipeline page.